Sana Biotechnology
A biotech company focused on creating and delivering engineered cells as medicine for patients.
Founded by former executives of Juno Therapeutics, Sana Biotech launched in 2019, with the goal of aggregating R&D and manufacturing capabilities across the cell and gene therapy treatment paradigms.
In April 2023, the company's President and CEO, Steve Harr, said that Sana is "making rapid progress in transitioning from a research-based company to one focused on delivering innovative gene and cell-based medicines to patients across multiple disease areas."
Latest Sana Biotechnology News & Features
12 February 2024
11 April 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze